These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 14767382)
1. TNF inhibitors: a new age in rheumatoid arthritis treatment. Anderson DL Am J Nurs; 2004 Feb; 104(2):60-8; quiz 68-9. PubMed ID: 14767382 [No Abstract] [Full Text] [Related]
2. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Anderson P; Louie J; Lau A; Broder M Curr Rheumatol Rep; 2005 Mar; 7(1):3-9. PubMed ID: 15760575 [No Abstract] [Full Text] [Related]
3. TNF-alpha inhibition: the need for a tumor necrosis factor thermostat. O'Dell JR Mayo Clin Proc; 2001 Jun; 76(6):573-5. PubMed ID: 11393494 [No Abstract] [Full Text] [Related]
4. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies]. González-Gay MA; Agudo M Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386 [No Abstract] [Full Text] [Related]
9. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al. Neovius M; Askling J Ann Rheum Dis; 2014 Jun; 73(6):e32. PubMed ID: 24638970 [No Abstract] [Full Text] [Related]
10. The 'alphabet' of rheumatoid arthritis treatment. Capriotti T Medsurg Nurs; 2004 Dec; 13(6):420-8. PubMed ID: 15714747 [No Abstract] [Full Text] [Related]
11. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs]. Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184 [TBL] [Abstract][Full Text] [Related]
12. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008 [TBL] [Abstract][Full Text] [Related]
13. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090 [TBL] [Abstract][Full Text] [Related]
14. Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al. Francis S; Block MJ Arthritis Rheum; 2010 Sep; 62(9):2826; author reply 2826-8. PubMed ID: 20556822 [No Abstract] [Full Text] [Related]
15. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750 [TBL] [Abstract][Full Text] [Related]
16. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept]. Tijhuis GJ; van de Putte LB; Breedveld FC Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312 [TBL] [Abstract][Full Text] [Related]